Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$348.1MCash on Hand
CF+ Cash Runway
Follow AXGN by emailGet an email when AXGN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about AXGN, unsubscribe in one click. Privacy
📣 What AXGN Says Is Next
fourth quarter · “The Company expects to report full results for the fourth quarter and year ended December 31, 2025, in late February 2026.”
Company press release, Jan 12, 2026 · SEC filing
fourth quarter · “Gross margin is expected to reflect one-time costs of approximately $1.9 million, or 3% and 1% for the fourth quarter and full-year 2025, respectively, related to the U.S. Food and Drug Administration (“FDA”) Biologics License Application (“BLA”) approval of Avance ® .”
Company press release, Jan 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 9, 2026 ·
Axogen posted a corporate presentation on its website for a prostate nerve reconstruction investor event, furnished as Exhibit 99.1 and shared with analysts and investors. The deck cites about 40% variable erectile function recovery after robotic prostatectomy and a $754m total addressable market. Form 8-K · SEC filing · Press release
Oct 28, 2026 ·
Earnings Reported Q3 2026 revenue of $75.8 million, up 26.2%, and net income of $2.3 million or $0.04 per share. Raised full-year 2026 revenue guidance to at least $290 million, growth of at least 29%, after closing an upsized offering with $225 million net proceeds and the BioCircuit acquisition. Form 8-K · SEC filing · Press release
Oct 28, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 1, 2026 ·
Deal Axogen completed its acquisition of BioCircuit Technologies, maker of NerveTape, the first FDA-cleared sutureless device for nerve repair. BioCircuit is expected to add about $6 million to Q4 2026 revenue and $34 million in 2027, not in prior guidance. Form 8-K · SEC filing · Press release
Sep 10, 2026 ·
Deal Axogen agreed to buy BioCircuit Technologies for $200.0 million in cash, subject to adjustments, with a $1.0 million holdback, expected to close in Q4 2026. Axogen also priced a public offering of 4,910,000 shares at $42.50 per share, with a 30-day option for 736,500 more. Form 8-K · SEC filing · Press release
Sep 10, 2026 ·
Deal Axogen filed an amendment to add the Agreement and Plan of Merger with BioCircuit Technologies, dated September 9, 2026, and to furnish a corrected investor presentation. BioCircuit has about $24 million run-rate revenue and roughly $11 million of 2025 revenue. Form 8-K/A · SEC filing · Press release
Sep 10, 2026 ·
Financing Axogen is offering 4,910,000 shares of common stock at $42.50 per share, for gross proceeds of $208,675,000 before underwriting discounts, with proceeds to fund the proposed acquisition of BioCircuit Technologies, Inc. Underwriters have a 30-day option to buy up to 736,500 additional shares. Form 424B5 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · N/A · Active Trial · Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends Registry primary completion date, not a results date
Nov 2028 · N/A · Active Trial · Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction Registry primary completion date, not a results date
Dec 2030 · Phase 4 · Recruiting · Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
AXGN holds $348.1M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Share count 59,730,715 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AXGN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.